Oncotarget

Research Papers:

Extracellular nicotinamide phosphoribosyltransferase (eNAMPT) is a novel marker for patients with BRAF-mutated metastatic melanoma

Valentina Audrito, Antonella Managò, Federica Zamporlini, Eliana Rulli, Federica Gaudino, Gabriele Madonna, Stefania D'Atri, Gian Carlo Antonini Cappellini, Paolo Antonio Ascierto, Daniela Massi, Nadia Raffaelli, Mario Mandalà and Silvia Deaglio _

PDF  |  HTML  |  Supplementary Files  |  How to cite  |  Order a Reprint

Oncotarget. 2018; 9:18997-19005. https://doi.org/10.18632/oncotarget.24871

Metrics: PDF 1368 views  |   HTML 1329 views  |   ?  


Abstract

Valentina Audrito1,2, Antonella Managò1,2, Federica Zamporlini3, Eliana Rulli4, Federica Gaudino1,2, Gabriele Madonna5, Stefania D'Atri6, Gian Carlo Antonini Cappellini7, Paolo Antonio Ascierto5, Daniela Massi8, Nadia Raffaelli3, Mario Mandalà9,* and Silvia Deaglio1,2,*

1Department of Medical Sciences, University of Turin, Turin, Italy

2Italian Institute for Genomic Medicine, Turin, Italy

3Department of Agricultural, Food and Environmental Sciences, Polytechnic University of Marche, Ancona, Italy

4Statistics Unit Methodology for Clinical research Laboratory, Oncology Department, IRCCS, Istituto di Ricerche Farmacologiche Mario Negri, Milan, Italy

5Melanoma, Cancer Immunotherapy and Innovative Therapies O.U., Istituto Nazionale Tumori IRCCS Fondazione "G. Pascale", Napoli, Italy

6Laboratory of Molecular Oncology, Istituto Dermopatico dell'Immacolata-IRCCS, Rome, Italy

7Department of Oncology and Dermatological Oncology, Istituto Dermopatico dell'Immacolata-IRCCS, Rome, Italy

8Division of Pathological Anatomy, Department of Surgery and Translational Medicine, University of Florence, Florence, Italy

9Unit of Medical Oncology, Department of Oncology and Hematology, Papa Giovanni XXIII Hospital, Bergamo, Italy

*Shared co-authorship

Correspondence to:

Silvia Deaglio, email: silvia.deaglio@unito.it; silvia.deaglio@iigm.it

Keywords: metastatic melanoma; tumor marker; prognosis; resistance to therapy; NAMPT

Received: October 19, 2017     Accepted: February 28, 2018     Published: April 10, 2018

ABSTRACT

Metastatic melanoma carrying BRAF mutations represent a still unmet medical need as success of BRAF inhibitors is limited by development of resistance. Nicotinamide phosphoribosyltransferase (NAMPT) is a key enzyme in NAD biosynthesis. An extracellular form (eNAMPT) possesses cytokine-like functions and is up-regulated in inflammatory disorders, including cancer. Here we show that eNAMPT is actively released in culture supernatants of melanoma cell lines. Furthermore, cells that become resistant to BRAF inhibitors (BiR) show a significant increase of eNAMPT levels. Plasma from mice xenografted with BiR cell lines contain higher eNAMPT levels compared to tumor-free animals. Consistently, eNAMPT levels are elevated in 113 patients with BRAF-mutated metastatic melanoma compared to 50 with localized disease or to 38 healthy donors, showing a direct correlation with markers of tumor burden, such as LDH, or aggressive disease (such as PD-L1). eNAMPT concentrations decrease in response to therapy with BRAF/MEK inhibitors, but increase again at progression, as inferred from the serial analysis of 50 patients. Lastly, high eNAMPT levels correlate with a significantly shorter overall survival.

Our findings suggest that eNAMPT is a novel marker of tumor burden and response to therapy in patients with metastatic melanoma carrying BRAF mutations.


Creative Commons License All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 3.0 License.
PII: 24871